Greenland Mines Ltd (GRML) Stock Price & Analysis
Greenland Mines Ltd (GRML) fell 3.94% to USD 0.19 as of July 25, 2026 at 09:57 UTC, according to Nexqual real-time market data.
GRML last closed at USD 0.2; the session ranged USD 0.19–0.24 on volume of 5,774,566 shares. Market capitalization is $28.99M, with a 52-week range of USD 0.16–1.28 (NCM). Source: Nexqual, July 25, 2026 at 09:57 UTC.
Key Statistics (as of July 25, 2026 at 09:57 UTC)
| Price | USD 0.19 |
|---|---|
| Change | ▼ 3.94% (down) |
| Previous Close | USD 0.2 |
| Open | USD 0.21 |
| Day Range | USD 0.19 – 0.24 |
| 52-Week Range | USD 0.16 – 1.28 |
| Volume | 5,774,566 shares |
| Market Cap | $28.99M |
| Exchange | NCM |
Technical Analysis (GRML)
Nexqual's technical model rates GRML "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 09:57 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.33 (neutral) |
| vs SMA50 | Below (USD 0.29) |
| MACD | -0.02 (negative) |
Analyst Ratings (GRML)
Wall Street analysts rate GRML "Strong Buy" based on 1 analysts, with a mean price target of USD 2.5 (range USD 2.5–2.5), per Nexqual as of July 25, 2026 at 09:57 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 2.5 |
| High Target | USD 2.5 |
| Low Target | USD 2.5 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (GRML)
Source: Nexqual, July 25, 2026 at 09:57 UTC.
Financials & Fundamentals (GRML)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -85.56% |
| Current Ratio | 19.74 |
| Total Cash | $10.00M |
| Total Debt | $0 |
| Free Cash Flow | $-5.53M |
Source: Nexqual, July 25, 2026 at 09:57 UTC.
Financial Health Score (GRML)
Nexqual rates Greenland Mines Ltd's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 09:57 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$9M |
| Efficiency | Critical — ROE -86%, ROA -30.0% |
Ownership (GRML)
| Insider Ownership | +14.75% |
|---|---|
| Institutional Ownership | +6.44% |
| Shares Outstanding | 150.53M |
| Float | 100.34M |
| Short % of Float | +5.72% |
Source: Nexqual, July 25, 2026 at 09:57 UTC.
Leadership (GRML)
Greenland Mines Ltd is led by Joseph A. Sinkule Pharm.D. (age 71), Founder, CEO, Chairman of the Board & Secretary, per Nexqual as of July 25, 2026 at 09:57 UTC.
| Founder, CEO, Chairman of the Board & Secretary | Joseph A. Sinkule Pharm.D. (age 71) |
|---|---|
| Chief Financial Officer | Jeffrey LeBlanc (age 48) |
| Medical Advisor & Director | Shalom Z. Hirschman (age 89) |
| President | Bo Moller Stensgaard (age 50) |
| Chief Scientific Officer & Consultant | Miguel Chillon Rodriguez (age 59) |
Major Backers & Investors (GRML)
Notable institutional backers of Greenland Mines Ltd include Meteora Capital, LLC, UBS Group AG, Fidelity, according to Nexqual as of July 25, 2026 at 09:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Meteora Capital, LLC | 3.89% |
| UBS Group AG | 0.78% |
| Fidelity | 0.43% |
| Two Sigma Securities, LLC | 0.15% |
| AM Investment Strategies, LLC | 0.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.11% |
| Geode Capital | 0.54% |
| State Street | 0.14% |
Source: Nexqual, July 25, 2026 at 09:57 UTC.
From Greenland Mines Ltd's Latest SEC 10-K Filing (filed 2026-04-01)
Key Strengths & Strategy (as disclosed to the SEC)
- Our cell and gene therapy platform consists of proprietary technology programs (patents issued and pending) that include a gene therapy program that uses a gene therapy approach to produce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative diseases and other diseases of aging (in-licensed pending patent applications from UAB).
Partnerships
- UAB and ICREA reserve the rights to use the licensed rights for internal non-commercial research and to allow other academic institutions to use the licensed rights for internal non-commercial research.    As set forth in the agreement, we are responsible for all costs associated with the research, development, and commercialization of the Products, including entering into a Sponsored Research agreement with Dr. Chillon's and Dr.
- Much of this work will be funded by the Sponsored Research Agreement with UAB in Barcelona.   Supplementation of this human Klotho protein by biologic infusion or by gene therapy may potentially treat many diseases and pathologies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCTI | Healthcare Triangle, Inc. | USD 1.62 | ▼ 7.95% |
| PLRZ | Polyrizon Ltd. | USD 14.68 | ▲ 2.02% |
| IXHL | Incannex Healthcare Inc. | USD 2.95 | ▼ 5.45% |
| TNON | Tenon Medical, Inc. | USD 0.19 | ▼ 3.65% |
| NIVF | NewGenIvf Group Limited | USD 1.1 | ▼ 13.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 09:57 UTC. This page is informational and not investment advice.